Apoptosis in cancer: from pathogenesis to treatment

Apoptosis is an ordered and orchestrated cellular process that occurs in physiological and pathological conditions. It is also one of the most studied topics among cell biologists. An understanding of the underlying mechanism of apoptosis is important as it plays a pivotal role in the pathogenesis of many diseases. In some, the problem is due to too much apoptosis, such as in the case of degenerative diseases while in others, too little apoptosis is the culprit. Cancer is one of the scenarios where too little apoptosis occurs, resulting in malignant cells that will not die. The mechanism of apoptosis is complex and involves many pathways. Defects can occur at any point along these pathways, leading to malignant transformation of the affected cells, tumour metastasis and resistance to anticancer drugs. Despite being the cause of problem, apoptosis plays an important role in the treatment of cancer as it is a popular target of many treatment strategies. The abundance of literature suggests that targeting apoptosis in cancer is feasible. However, many troubling questions arise with the use of new drugs or treatment strategies that are designed to enhance apoptosis and critical tests must be passed before they can be used safely in human subjects.

[1]  S. Fulda,et al.  Deficient activation of the CD95 (APO-1/Fas) system in drug-resistant cells , 1997, Leukemia.

[2]  J. Sabourin,et al.  Role of bax mutations in apoptosis in colorectal cancers with microsatellite instability. , 2005, American journal of clinical pathology.

[3]  G. Karp.  Cell and molecular biology : concepts and experiments / Gerald Karp , 1996 .

[4]  E. Kimby,et al.  Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia , 2008, Investigational New Drugs.

[5]  Shaomeng Wang,et al.  Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. , 2009, Annual review of pharmacology and toxicology.

[6]  S. Fulda,et al.  Chemosensitivity of solid tumor cells in vitro is related to activation of the CD95 system , 1998, International journal of cancer.

[7]  Lee Baker,et al.  Discovery, In Vivo Activity, and Mechanism of Action of a Small-Molecule p53 Activator , 2007, Cancer cell.

[8]  Wei-Guo Zhu,et al.  p53: Structure, Function and Therapeutic Applications , 2006 .

[9]  Liu Liu,et al.  Cyclopeptide Smac mimetics as antagonists of IAP proteins. , 2010, Bioorganic & medicinal chemistry letters.

[10]  John Calvin Reed.  Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies. , 1997, Seminars in hematology.

[11]  D. Hallahan,et al.  XIAP and survivin as therapeutic targets for radiation sensitization in preclinical models of lung cancer , 2004, Oncogene.

[12]  P. Zatloukal,et al.  Increased expression of inhibitor of apoptosis proteins, survivin and XIAP, in non-small cell lung carcinoma. , 2009, International journal of oncology.

[13]  M. Hengartner.  Apoptosis Corralling the Corpses , 2001, Cell.

[14]  Galina Selivanova,et al.  Characterization of the p53-rescue drug CP-31398 in vitro and in living cells , 2002, Oncogene.

[15]  R. Schiestl,et al.  siRNA Targeting NBS1 or XIAP Increases Radiation Sensitivity of Human Cancer Cells Independent of TP53 Status , 2006, Radiation research.

[16]  S. Korsmeyer,et al.  Cell Death Critical Control Points , 2004, Cell.

[17]  V. Dragowska,et al.  Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  Afshin Samali,et al.  Caspase-12 and ER-stress-mediated apoptosis: the story so far. , 2003, Annals of the New York Academy of Sciences.

[19]  P. Groscurth,et al.  Morphological features of cell death. , 2004, News in physiological sciences : an international journal of physiology produced jointly by the International Union of Physiological Sciences and the American Physiological Society.

[20]  H. Boezen,et al.  Death receptors and ligands in cervical carcinogenesis: an immunohistochemical study. , 2005, Gynecologic oncology.

[21]  P. Krammer,et al.  Death receptor signaling , 2005, Journal of Cell Science.

[22]  S. Sen,et al.  Antisense-mediated downregulation of anti-apoptotic proteins induces apoptosis and sensitizes head and neck squamous cell carcinoma cells to chemotherapy , 2005 .

[23]  D. Schuppan,et al.  Variants of bcl-2 specific siRNA for silencing antiapoptotic bcl-2 in pancreatic cancer , 2005, Gut.

[24]  G. Häcker.  The morphology of apoptosis , 2000, Cell and Tissue Research.

[25]  H. Johnsen,et al.  Vaccination with p53-peptide–pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study , 2004, Cancer Immunology, Immunotherapy.

[26]  Jie Sun,et al.  [Inhibitory effects of the survivin siRNA transfection on human lung adenocarcinoma cells SPCA1 and SH77]. , 2011, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

[27]  Dajun Yang,et al.  Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition , 2008, Proceedings of the National Academy of Sciences.

[28]  D. Spandidos,et al.  The anti-CD20 mAb LFB-R603 interrupts the dysregulated NF-κB/Snail/RKIP/PTEN resistance loop in B-NHL cells: role in sensitization to TRAIL apoptosis. , 2011, International journal of oncology.

[29]  S. H. van der Burg,et al.  Immunological and Clinical Effects of Vaccines Targeting p53-Overexpressing Malignancies , 2011, Journal of biomedicine & biotechnology.

[30]  Yong Zhu,et al.  Silencing of Bmi-1 gene by RNA interference enhances sensitivity to doxorubicin in breast cancer cells. , 2011, Indian journal of experimental biology.

[31]  S. Miyatake,et al.  Downregulation of survivin by siRNA diminishes radioresistance of pancreatic cancer cells. , 2005, Surgery.

[32]  Jennifer R. Brown,et al.  Novel agents for the treatment of chronic lymphocytic leukemia. , 2010, Clinical advances in hematology & oncology : H&O.

[33]  S. Sen,et al.  Antisense-mediated downregulation of anti-apoptotic proteins induces apoptosis and sensitizes head and neck squamous cell carcinoma cells to chemotherapy. , 2005, Cancer biology & therapy.

[34]  H. Perlman,et al.  Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. , 1995, Cancer research.

[35]  M. Narita,et al.  Cancer gene therapy using a pro-apoptotic gene, caspase-3 , 1999, Gene Therapy.

[36]  L. David Tomei,et al.  Apoptosis: The Molecular Basis of Cell Death , 1991 .

[37]  A. Wyllie,et al.  Apoptosis: A Basic Biological Phenomenon with Wide-ranging Implications in Tissue Kinetics , 1972, British Journal of Cancer.

[38]  K. Shiraki,et al.  Targeting of X-linked inhibitor of apoptosis protein or survivin by short interfering RNAs sensitize hepatoma cells to TNF-related apoptosis-inducing ligand- and chemotherapeutic agent-induced cell death. , 2005, Oncology reports.

[39]  W. Hong,et al.  Retrovirus–mediated wild–type P53 gene transfer to tumors of patients with lung cancer. , 1996, Nature Medicine.

[40]  T. Fan,et al.  Inhibitor of apoptosis proteins and apoptosis. , 2008, Acta biochimica et biophysica Sinica.

[41]  Shaomeng Wang,et al.  Therapeutic Potential and Molecular Mechanism of a Novel, Potent, Nonpeptide, Smac Mimetic SM-164 in Combination with TRAIL for Cancer Treatment , 2011, Molecular Cancer Therapeutics.

[42]  Carol Porth,et al.  Pathophysiology: Concepts of Altered Health States , 1982 .

[43]  S. Baird,et al.  IAP-targeted therapies for cancer , 2008, Oncogene.

[44]  G. Evan,et al.  15 Methods for Detecting and Quantifying Apoptosis , 1997 .

[45]  Kazufumi Suzuki,et al.  Recent Advances in p53 Research and Cancer Treatment , 2011, Journal of biomedicine & biotechnology.

[46]  D. B. Yehuda,et al.  Two splicing variants of a new inhibitor of apoptosis gene with different biological properties and tissue distribution pattern , 2001, FEBS letters.

[47]  J. Rohn,et al.  The viral death effector Apoptin reveals tumor-specific processes , 2004, Apoptosis.

[48]  D. Lane,et al.  p53, guardian of the genome , 1992, Nature.

[49]  G. Salvesen,et al.  ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas , 2000, Current Biology.

[50]  V. Rotter,et al.  Introduction: p53 – the first twenty years , 1999, Cellular and Molecular Life Sciences CMLS.

[51]  S. Tsao,et al.  Caspase activity is downregulated in choriocarcinoma: a cDNA array differential expression study , 2006, Journal of Clinical Pathology.

[52]  Rodney J Scott,et al.  P53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation , 2011, BMC Cancer.

[53]  A. Saraste,et al.  Morphologic and biochemical hallmarks of apoptosis. , 2000, Cardiovascular research.

[54]  T. Lawrence,et al.  Overcoming cancer therapy resistance by targeting inhibitors of apoptosis proteins and nuclear factor-kappa B. , 2009, American journal of translational research.

[55]  M. Schuler,et al.  Generating p53-specific cytotoxic T lymphocytes by recombinant adenoviral vector-based vaccination in mice, but not man , 2002, Gene Therapy.

[56]  P. Hamilton,et al.  Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance. , 1998, British Journal of Cancer.

[57]  P. Horellou,et al.  Gene transfer of constitutively active caspase‐3 induces apoptosis in a human hepatoma cell line , 2005, The journal of gene medicine.

[58]  Harsh Mohan.  A TEXTBOOK OF PATHOLOGY , 1939 .

[59]  S. Hoda,et al.  Robbins and Cotran Pathologic Basis of Disease , 2005, American Journal of Clinical Pathology.

[60]  Hua-Qin Wang,et al.  Antisurvivin oligonucleotides inhibit growth and induce apoptosis in human medullary thyroid carcinoma cells , 2006, Experimental & Molecular Medicine.

[61]  W. Fairbrother,et al.  The Inhibitor of Apoptosis Proteins as Therapeutic Targets in Cancer , 2007, Clinical Cancer Research.

[62]  Paul Timpson,et al.  Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer , 2010, Proceedings of the National Academy of Sciences.

[63]  R. Kirby,et al.  Apoptosis: A review of pro‐apoptotic and anti‐apoptotic pathways and dysregulation in disease , 2008, Journal of Veterinary Emergency and Critical Care.

[64]  L. Wang,et al.  Downregulation of caspase‐9 is a frequent event in patients with stage II colorectal cancer and correlates with poor clinical outcome , 2010, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[65]  S. Helfand,et al.  New tricks of an old molecule: lifespan regulation by p53 , 2006, Aging cell.

[66]  S. Fulda,et al.  Targeting apoptosis pathways in cancer therapy. , 2004, Current cancer drug targets.

[67]  Lorenzo Galluzzi,et al.  Mitochondrial membrane permeabilization in cell death. , 2007, Physiological reviews.

[68]  R A Knight,et al.  Classification of cell death: recommendations of the Nomenclature Committee on Cell Death , 2005, Cell Death and Differentiation.

[69]  D. P. Bentley,et al.  Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance. , 1997, British Journal of Cancer.

[70]  Tania L. Slatter,et al.  Hyperproliferation, cancer, and inflammation in mice expressing a Δ133p53-like isoform. , 2011, Blood.

[71]  M-F Chen,et al.  Adenovirus-mediated transfer of siRNA against survivin enhances the radiosensitivity of human non-small cell lung cancer cells , 2008, Cancer Gene Therapy.

[72]  P. Nowell,et al.  Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. , 1984, Science.

[73]  G. Dewson,et al.  Bcl-2 family-regulated apoptosis in health and disease , 2010 .

[74]  T. Tsuruo,et al.  A human IAP-family gene, apollon, expressed in human brain cancer cells. , 1999, Biochemical and biophysical research communications.

[75]  D. Lane,et al.  The p53 tumour suppressor gene , 1998, The British journal of surgery.

[76]  S. Korsmeyer,et al.  An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.

[77]  J. Tschopp,et al.  Apoptosis induced by death receptors. , 2000, Pharmaceutica acta Helvetiae.

[78]  Frank M Boeckler,et al.  Targeted rescue of a destabilized mutant of p53 by an in silico screened drug , 2008, Proceedings of the National Academy of Sciences.

[79]  S. Korsmeyer,et al.  BCL-2 family members and the mitochondria in apoptosis. , 1999, Genes & development.

[80]  A. Eastman,et al.  Multiple BH3 Mimetics Antagonize Antiapoptotic MCL1 Protein by Inducing the Endoplasmic Reticulum Stress Response and Up-regulating BH3-only Protein NOXA* , 2011, The Journal of Biological Chemistry.

[81]  Zan Huang,et al.  Overexpression of Survivin Initiates Hematologic Malignancies In Vivo , 2010, Leukemia.

[82]  R A Knight,et al.  Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009 , 2005, Cell Death and Differentiation.

[83]  W. Bodmer,et al.  p53 mutations in colorectal cancer. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[84]  Inna N Lavrik,et al.  Caspases: pharmacological manipulation of cell death. , 2005, The Journal of clinical investigation.

[85]  J. McNiff,et al.  Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. , 1999, The Journal of investigative dermatology.

[86]  P. Chène.  p53 as a drug target in cancer therapy , 2001 .

[87]  T. Crook,et al.  The p53 pathway in breast cancer , 2002, Breast Cancer Research.

[88]  J. Kerr.  Definition and incidence of apoptosis : A historical perspective , 1991 .

[89]  S. Fulda.  Evasion of Apoptosis as a Cellular Stress Response in Cancer , 2010, International journal of cell biology.

[90]  G. Majno,et al.  Apoptosis, oncosis, and necrosis. An overview of cell death. , 1995, The American journal of pathology.

[91]  Fan Zhang,et al.  Down-regulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance , 2002, Oncogene.

[92]  B. Cookson,et al.  Apoptosis, Pyroptosis, and Necrosis: Mechanistic Description of Dead and Dying Eukaryotic Cells , 2005, Infection and Immunity.

[93]  G. Evan,et al.  Methods for detecting and quantifying apoptosis. , 1998, Current topics in developmental biology.

[94]  M. Los,et al.  Caspases and cancer: mechanisms of inactivation and new treatment modalities. , 2004, Experimental oncology.

[95]  Andy J. Minn,et al.  Bcl-xL forms an ion channel in synthetic lipid membranes , 1997, Nature.

[96]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[97]  C. Reynolds,et al.  Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer Therapy , 2009, Clinical Cancer Research.

[98]  F. Khuri,et al.  Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. , 2000, Cancer research.

[99]  L. Zitvogel,et al.  Cell death modalities: classification and pathophysiological implications , 2007, Cell Death and Differentiation.

[100]  C. Rudin,et al.  Expression of bcl-xL can confer a multidrug resistance phenotype. , 1995, Blood.

[101]  S. Fulda,et al.  Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression , 2002, Oncogene.

[102]  D. Vaux,et al.  Mammalian mitochondrial IAP binding proteins. , 2003, Biochemical and biophysical research communications.

[103]  I. McNeish,et al.  Expression of the IAP protein family is dysregulated in pancreatic cancer cells and is important for resistance to chemotherapy , 2007, International journal of cancer.

[104]  Xiaohua Li,et al.  Inhibitory effect of recombinant adenovirus carrying immunocaspase-3 on hepatocellular carcinoma. , 2007, Biochemical and biophysical research communications.

[105]  M. Tallman,et al.  Bcl‐2 regulatory pathway is functional in chronic lymphocytic leukemia , 2005, Cytometry. Part B, Clinical cytometry.

[106]  K. Rai,et al.  Effect of the addition of oblimersen (Bcl-2 antisense) to fludarabine/cyclophosphamide for relapsed/refractory chronic lymphocytic leukemia (CLL) on survival in patients who achieve CR/nPR: Five-year follow-up from a randomized phase III study , 2008 .

[107]  N. Zaffaroni,et al.  Targeting survivin in cancer therapy: fulfilled promises and open questions. , 2007, Carcinogenesis.